Objectives:

The overall objective is to determine if the adolescent MenACWY booster in different Canadian provincial schedules provides protection at Grade 12 (age 16-17 years), as students enter the high-risk period. We will assess the initial booster response and antibody persistence following a single dose of MenACWY conjugate vaccine, comparing: (i) adolescents primed with different MenC conjugate vaccine schedules; and (ii) immunogenicity of -CRM, -DT and -TT MenACWY conjugate vaccines.

Project Lead:
Dr. Manish Sadarangani